Product Liability Lawyer and Pharmaceutical Injury Attorney reviews SGLT-2 Diabetes Drug Injury Lawsuits & Added Amputation Risk for Diabetes Patients


Recent medical studies involving diabetic patients using SGLT-2 inhibitors like Invokana, Invokamet (includes Metformin), Synjardy, Farxiga, Xigduo, Jardiance and Glyxambi show patients at an increased risk of lower limb amputation, Fournier’s Gangrene, bone fractures, kidney and liver failure and heart attacks.

The New England Journal of Medicine published a recent report that concludes SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are associated with approximately twice the risk of diabetic ketoacidosis as DPP4 inhibitors, another option for diabetes patients.

Since two clinical studies demonstrated a link between one SGLT-2 drug, Invokana, and an elevated risk of lower limb amputations, the U.S. Food and Drug Administration (FDA) has advised prescribing doctors to discontinue the medication for patients who experience unusual pain, sores or lower extremity infection.

This class of diabetes drugs is relatively new, but already hundreds of injury claims have been filed against pharmaceutical companies by individual patients. Patients are reporting kidney damage, Fournier’s Gangrene, amputations, ketoacidosis and heart attack events. Attorneys claim the drug manufacturers involved have failed to properly warn consumers and doctors of the SGLT-2 drug injury risks and failed to properly test the medication before selling it to the public.

Joe Lyon is a highly-rated product liability lawyer representing plaintiffs nationwide in a wide variety of SGLT-2 diabetes drug injury lawsuits and civil litigation claims against pharmaceutical companies.  


What Are SGLT-2 Inhibitor Drugs?

There are several medications available on the U.S. market prescribed to patients with Type 2 diabetes, and sometimes, Type 1, which help lower blood sugar levels. SGLT-2 inhibitor (sodium-glucose cotransporter-2 inhibitor) drugs function by assisting a patient’s kidneys discard sugar from the body. The most popular SLGT-2 inhibitors on the market include the following brand names:

•    Invokana
•    Invokamet
•    Invokamet XR
•    Farxiga
•    Xigduo XR
•    Jardiance
•    Glyxambi


SGLT2 Amputation Risk & Fournier’s Gangrene

Recent research of one SGLT-2 inhibitor called Invokana concluded that the risk of amputation doubled during drug use in some patients. Individuals taking any SGLT-2 inhibitor should remain vigilant for signs of increased tenderness, sores, ulcers, and infections in the lower extremities. Immediately notify a medical professional if such symptoms appear. The FDA has warned of several severe side effects including Fournier’s Gangrene infection.

Other serious complications of SGLT-2 medications may include the following:

•    Amputation
•    Renal Failure
•    Ketoacidosis
•    Kidney Failure
•    Heart Attacks
•    Fournier’s Gangrene
•    High amounts of potassium in the blood
•    Serious urinary tract infections
•    Low blood sugar when combined with other diabetes medicine
•    Yeast infections
•    Bone fractures
•    Increased cholesterol


Amputation & SGLT-2 Diabetes Drug Injury Lawsuits

Since this class of Type 2 diabetes drugs was released, the FDA has issued a series of warnings to patients and doctors about the risks that have been downplayed by the drug makers. The active agents in the drugs, Dapagliflozin, Canagliflozin, and Empagliflozin have all been assessed by the FDA for potential carcinogenicity. The FDA is concerned with all reported adverse effects of the drug, including bone fractures, kidney issues, heart attacks, and amputations.

diabetes drug injury lawsuits cincinnati opioid abuse lawsuits nursing home overmedication risperdal side effects skid steer injury defective stryker hip implants xeljanz fda warnings pulmonary fibrosis lawyer

In 2015, a U.S. Food and Drug Administration (FDA) safety review resulted in adding warnings to the labels of SGLT-2 inhibitors regarding the risks of too much acid in the blood and of serious urinary tract infections. The FDA identified 19 cases of life-threatening blood infections and kidney infections that started as urinary tract infections with the SGLT-2 inhibitors. Some patients required admission to an intensive care unit in order to treat kidney failure.

A 2017 FDA warning issued on the label of Invokana, the most widely-sold SGLT-2 inhibitor, suggests physicians carefully consider certain factors before prescribing the drug, because some patients may be predisposed to amputations and other serious complications. The drug makers have not yet completely recalled any products even as consumers are gravely injured.


If you or a loved one has suffered an SGLT-2 drug injury, and have questions about the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403. You will speak directly with Mr. Lyon, and he will help you answer critical questions regarding SGLT-2 diabetes drug injury lawsuits.